Loading...
01/11 08:24
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance with a 135% increase in CARVYKTI sales and a robust cash position. While management was vague on some specifics, the overall sentiment is positive due to strong demand trends, strategic partnerships, and promising safety and efficacy profiles for CARVYKTI. The focus on community expansion and operational breakeven by 2025 further supports a positive outlook.
CARVYKTI net trade sales $439 million during the second quarter, a 136% increase year-over-year. Reasons for the increase include strong demand, capacity expansion, and increased utilization in earlier line settings.
U.S. net trade sales $358 million, a 114% year-over-year increase and 13% quarter-over-quarter growth. Growth was driven by strong demand and nearly 60% utilization in earlier line settings.
Outside U.S. (OUS) sales $81 million, 4x the amount over the same period a year ago and a 59% quarter-over-quarter increase. Growth was driven by expansion in Germany, Switzerland, Austria, Brazil, and new launches in Spain, Denmark, Sweden, Belgium, Portugal, Israel, and the U.K.
Gross margin on net product sales 57% for the second quarter. No specific reasons for change mentioned.
R&D expense $98 million, 39% of revenue, slightly declined from the prior year. Reasons include disciplined expense management while continuing to invest in the pipeline and manufacturing capacity.
SG&A expense $81 million, 32% of revenue, a 23% increase from the prior year. Reasons include supporting the second-line indication launch and manufacturing capacity.
Operating loss $22 million, reduced by almost half from $41 million in the same period 1 year ago. Reasons include operational efficiency and disciplined expense management.
Adjusted net income $10 million, compared to a net loss of $125 million (including $111 million unrealized foreign exchange loss). Reasons include operational efficiency and strong commercial execution.
CARVYKTI net trade sales: Achieved $439 million in Q2 2025, a 136% increase year-over-year, marking the highest CAR-T sales in a single quarter.
Pipeline candidates: Phase I study of LB1908 showed encouraging antitumor activity with manageable safety. LB2102 demonstrated no dose-limiting toxicity and preliminary efficacy signals.
New platform TaVec: Targeting oncology and autoimmune indications with T-cell specificity and safety. Initial trials for non-Hodgkin's lymphoma underway.
Global expansion of CARVYKTI: Sales outside the U.S. reached $81 million, a 4x increase year-over-year. Expanded to markets like Spain, Denmark, Sweden, Belgium, Portugal, Israel, and the U.K.
Manufacturing capacity: Approval for Raritan expansion expected by year-end. Tech Lane facility to start commercial production for Europe later this year.
Operational efficiency: Operating loss reduced from $41 million to $22 million year-over-year. Gross margin on net product sales at 57%.
Manufacturing success rate: Maintained a 97% success rate with a 30-day turnaround time, among the best in the CAR-T industry.
Regulatory updates: FDA removed REMS for BCMA- and CD19-directed CAR-T therapies, improving patient access and experience.
Community treatment expansion: Activated 123 U.S. treatment sites, including partnerships with community practices like Virginia Oncology Associates.
Focus on frontline settings: CARTITUDE-5 and CARTITUDE-6 trials aim to move CARVYKTI into frontline treatment settings.
Regulatory and Compliance Risks: The FDA's decision to remove risk evaluation and mitigation strategies (REMS) for certain CAR-T therapies, including CARVYKTI, could lead to increased scrutiny or potential regulatory changes in the future. Additionally, the company must ensure compliance with updated monitoring requirements to avoid any regulatory setbacks.
Manufacturing and Supply Chain Risks: While the company has a high manufacturing success rate of 97%, any disruptions in the supply chain or delays in the approval of new manufacturing facilities (e.g., Raritan and Tech Lane) could impact the ability to meet growing demand for CARVYKTI.
Market Competition: The CAR-T therapy market is highly competitive, and the company faces pressure to maintain its market leadership. Competitors could introduce new therapies with superior efficacy or safety profiles, potentially impacting CARVYKTI's market share.
Financial Risks: Despite strong revenue growth, the company reported a net loss of $125 million in Q2 2025. Unrealized foreign exchange losses and high R&D and SG&A expenses could pose challenges to achieving profitability by 2026 as planned.
Operational Risks: The company is expanding its treatment sites and manufacturing facilities, which requires significant operational coordination. Any mismanagement or delays in these expansions could hinder the company's ability to scale effectively.
Strategic Execution Risks: The company is investing heavily in new research facilities and next-generation cell therapy platforms like TaVec. Any delays or failures in these initiatives could impact long-term growth and innovation.
Operational breakeven for CARVYKTI: The company anticipates achieving operational breakeven for CARVYKTI by the end of 2025.
Company-wide profitability: Legend Biotech expects to achieve company-wide profitability in 2026, excluding unrealized foreign exchange gains or losses.
Regulatory updates for CARVYKTI: The FDA has removed risk evaluation and mitigation strategies (REMS) for BCMA- and CD19-directed autologous CAR-T therapies, including CARVYKTI. This update is expected to improve patient experience and access.
CARTITUDE-6 trial: Legend Biotech expects to complete enrollment for the CARTITUDE-6 trial in 2025, which is key to moving CARVYKTI into the frontline setting.
Manufacturing capacity expansion: The company expects to receive approval for physical expansion in Raritan and initiate commercial production at the Tech Lane facility later in 2025 to meet increasing demand.
Global patient reach: Legend Biotech estimates a global patient opportunity of over 100,000 patients for CARVYKTI in second to fourth-line multiple myeloma treatment.
New research facility in Philadelphia: The company is building a new research facility in Philadelphia, focusing on in vivo delivery and next-generation off-the-shelf therapies for incurable diseases.
TaVec platform development: Legend Biotech is advancing its TaVec platform for oncology and autoimmune indications, with plans for multiple U.S. IND-enabling studies in the future.
The selected topic was not discussed during the call.
The earnings call highlights operational breakeven for CARVYKTI and company-wide profitability by 2026, which are positive indicators. The removal of REMS by the FDA, expansion plans, and strong demand in international markets further support a positive outlook. However, management's reluctance to provide specific timelines and details in some areas tempers expectations. Overall, the strategic plan and Q&A insights suggest a positive sentiment, likely resulting in a stock price increase of 2% to 8%.
The earnings call highlights strong financial performance with a 135% increase in CARVYKTI sales and a robust cash position. While management was vague on some specifics, the overall sentiment is positive due to strong demand trends, strategic partnerships, and promising safety and efficacy profiles for CARVYKTI. The focus on community expansion and operational breakeven by 2025 further supports a positive outlook.
The earnings call highlights strong sales growth, improved margins, and a solid cash position, indicating financial health. The strategic focus on pipeline expansion and capacity growth, alongside optimistic guidance, supports future profitability. Q&A insights reveal high demand and strategic efforts to meet challenges, though some management responses were vague. Overall, the company's prospects appear positive, with potential for stock price gains.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
